Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Operations (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash from Operations for 16 consecutive years, with 2090000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Operations fell 109.84% to 2090000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 5544000.0 through Sep 2025, down 14.05% year-over-year, with the annual reading at 4795000.0 for FY2025, 7.77% up from the prior year.
  • Cash from Operations for Q3 2025 was 2090000.0 at IGC Pharma, down from 1407000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 526000.0 in Q1 2024, with the low at 2505000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 1605526.32, with a median of 1618000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations surged 65.33% in 2024, then plummeted 109.84% in 2025.
  • Over 5 years, Cash from Operations stood at 2422000.0 in 2021, then soared by 31.96% to 1648000.0 in 2022, then grew by 3.7% to 1587000.0 in 2023, then increased by 17.01% to 1317000.0 in 2024, then plummeted by 58.69% to 2090000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2090000.0, 1407000.0, and 730000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.